Genelux Investor Presentation Deck
The Most Advanced Non-local Delivery Oncolytic Immunotherapy
Olvi-Vec: Engineered to selectively target and eliminate tumor cells while
inducing a robust patient-specific immune response
■
Physician-preferred Routes
of Delivery
Regional and systemic administration to
preferentially locate, colonize and destroy
tumor cells
In Ovarian Cancer trials, catheter
placement is prior to chemotherapy, with
removal 2 days after initial placement.
IV therapy currently being used in small
cell lung cancer Phase 1 trial.
GENELUX
Antitumor Effect
and Well Tolerated
Strong data in Phase 1b/2 study in
platinum-resistant/refractory ovarian
cancer (PRROC)
No Maximum Tolerated Dose (MTD)
observed+
Potential utility in multiple cancers
(demonstrated in 20 pre-clinical tumor
models), including metastatic disease
Rey
Ideal Backbone of
Combination Therapy
Turns tumors "hot" by localized inflammation
and induction of the influx of tumor
infiltrating lymphocytes (TILs)
Positively modulates anti-tumor pathways in
tumor microenvironment
4View entire presentation